Merck says new growth opportunities to drive revenue of $70 billion by mid-2030sJan 12 (Reuters) - Merck MRK.N said on Monday it has raised its outlook for new growth drivers, forecasting $70 billion in revenue from these fresh businesses by the mid-2030s, as it accelerates the launch of additional drugs ahead of looming competition to its blockbuster cancer therapy Keytruda.
The drugmaker now expects cardiometabolic and respiratory treatments to generate about $20 billion in sales, up from a previous forecast of $15 billion, while infectious disease drugs are projected to contribute roughly $15 billion, compared with an earlier estimate of $5 billion.
(Reporting by Chris Thomas in Mexico City; Editing by Sherry Jacob-Phillips)
((chris.thomas@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments